Restrictive measure for the commercialization of antimicrobials in Brazil: results achieved.

Autor:	Costa JMD; Universidade Federal de Minas Gerais. Faculdade de Farmácia. Programa de Pós-Graduação em Medicamentos e Assistência Farmacêutica. Belo Horizonte, MG, Brasil., Moura CS; McGill University. Division of Clinical Epidemiology. Department of Epidemiology. Montreal, Quebec, Canada., Pádua CAM; Universidade Federal de Minas Gerais. Faculdade de Farmácia. Departamento de Farmácia Social. Belo Horizonte, MG, Brasil., Vegi ASF; McGill University. Division of Clinical Epidemiology. Department of Epidemiology. Montreal, Quebec, Canada., Magalhães SMS; Universidade Federal de Minas Gerais. Faculdade de Farmácia. Departamento de Farmácia Social. Belo Horizonte, MG, Brasil., Rodrigues MB; Universidade Federal de Minas Gerais. Faculdade de Farmácia. Departamento de Farmácia Social. Belo Horizonte, MG, Brasil., Ribeiro AQ; Universidade Federal de Viçosa. Centro de Ciências Biológicas e da Saúde. Departamento de Nutrição e Saúde. Viçosa, MG, Brasil.
Jazyk:	English; Portuguese
Zdroj:	Revista de saude publica [Rev Saude Publica] 2019 Aug 19; Vol. 53, pp. 68. Date of Electronic Publication: 2019 Aug 19.
DOI:	10.11606/s1518-8787.2019053000879
Abstrakt:	Objective: To assess whether the incidence of hospital infection by a resistant microorganism decreased after the implementation of the restrictive measure of the National Health Surveillance Agency for the commercialization of antimicrobials. Methods: A historical cohort study of medical records of adult patients admitted to a general and public hospital from May 2010 to July 2011. A cohort was formed with patients admitted in the period before the restrictive measure for the commercialization of antimicrobials (Phase I) and a second cohort was formed with patients admitted after the implementation of the restrictive measure (Phase II). Results: The instantaneous risk of hospital infection by a resistant microorganism was estimated at seven by 1,000 people-time (95%CI 0.006-0.008) in Phase I, and four by 1,000 people-time (95%CI 0.003-0.005) in Phase II of the study. The differences between the survival curves in the different phases of the study and stratified by age group were also significant (p < 0.05). Conclusions: The results suggest that the implementation of the restrictive measure of the commercialization of antimicrobials by the National Health Surveillance Agency reduced the incidence of hospital infection by a resistant microorganism.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu